🚀 VC round data is live in beta, check it out!
Seres Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Seres Therapeutics and similar public comparables like Pliant Therapeutics, PolyPid, Lytix Biopharma, Eco Animal Health Group and more.
Seres Therapeutics Overview
About Seres Therapeutics
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Founded
2010
HQ
Employees
233
Website
Sectors
Financials (LTM)
EV
$121M
Seres Therapeutics Financials
Seres Therapeutics reported last 12-month revenue of $573K.
In the same LTM period, Seres Therapeutics generated had net loss of ($16M).
Revenue (LTM)
Seres Therapeutics P&L
In the most recent fiscal year, Seres Therapeutics reported revenue of $789K and EBITDA of $10M.
Seres Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $573K | XXX | $789K | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($6M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (729%) | XXX | XXX | XXX |
| EBITDA | — | XXX | $10M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 1246% | XXX | XXX | XXX |
| EBIT Margin | (15483%) | XXX | (11910%) | XXX | XXX | XXX |
| Net Profit | ($16M) | XXX | $6M | XXX | XXX | XXX |
| Net Margin | (2766%) | XXX | 722% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Seres Therapeutics Stock Performance
Seres Therapeutics has current market cap of $83M, and enterprise value of $121M.
Market Cap Evolution
Seres Therapeutics' stock price is $8.71.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $121M | $83M | -1.0% | XXX | XXX | XXX | $0.59 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSeres Therapeutics Valuation Multiples
Seres Therapeutics trades at 210.7x EV/Revenue multiple, and 12.3x EV/EBITDA.
EV / Revenue (LTM)
Seres Therapeutics Financial Valuation Multiples
As of April 11, 2026, Seres Therapeutics has market cap of $83M and EV of $121M.
Equity research analysts estimate Seres Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Seres Therapeutics has a P/E ratio of (5.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $83M | XXX | $83M | XXX | XXX | XXX |
| EV (current) | $121M | XXX | $121M | XXX | XXX | XXX |
| EV/Revenue | 210.7x | XXX | 153.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 12.3x | XXX | XXX | XXX |
| EV/EBIT | (1.4x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (21.0x) | XXX | XXX | XXX |
| P/E | (5.3x) | XXX | 14.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 139.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Seres Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Seres Therapeutics Margins & Growth Rates
Seres Therapeutics' revenue in the last 12 month declined by (100%).
Seres Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Seres Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 1246% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (108%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5955% | XXX | 4963% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8799% | XXX | 6218% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 11181% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Seres Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pliant Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| PolyPid | XXX | XXX | XXX | XXX | XXX | XXX |
| Lytix Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Eco Animal Health Group | XXX | XXX | XXX | XXX | XXX | XXX |
| OKYO Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Seres Therapeutics M&A Activity
Seres Therapeutics acquired XXX companies to date.
Last acquisition by Seres Therapeutics was on XXXXXXXX, XXXXX. Seres Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Seres Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSeres Therapeutics Investment Activity
Seres Therapeutics invested in XXX companies to date.
Seres Therapeutics made its latest investment on XXXXXXXX, XXXXX. Seres Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Seres Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Seres Therapeutics
| When was Seres Therapeutics founded? | Seres Therapeutics was founded in 2010. |
| Where is Seres Therapeutics headquartered? | Seres Therapeutics is headquartered in United States. |
| How many employees does Seres Therapeutics have? | As of today, Seres Therapeutics has over 233 employees. |
| Who is the CEO of Seres Therapeutics? | Seres Therapeutics' CEO is Thomas J. DesRosier. |
| Is Seres Therapeutics publicly listed? | Yes, Seres Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Seres Therapeutics? | Seres Therapeutics trades under MCRB ticker. |
| When did Seres Therapeutics go public? | Seres Therapeutics went public in 2015. |
| Who are competitors of Seres Therapeutics? | Seres Therapeutics main competitors are Pliant Therapeutics, PolyPid, Lytix Biopharma, Eco Animal Health Group. |
| What is the current market cap of Seres Therapeutics? | Seres Therapeutics' current market cap is $83M. |
| What is the current revenue of Seres Therapeutics? | Seres Therapeutics' last 12 months revenue is $573K. |
| What is the current revenue growth of Seres Therapeutics? | Seres Therapeutics revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Seres Therapeutics? | Current revenue multiple of Seres Therapeutics is 210.7x. |
| Is Seres Therapeutics profitable? | No, Seres Therapeutics is not profitable. |
| What is the current net income of Seres Therapeutics? | Seres Therapeutics' last 12 months net income is ($16M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.